One such commonly used medication for dermatologic and rheumatologic inflammatory conditions is hydroxychloroquine (Plaquenil), a chloroquine derivative. It is used to treat many diseases including malaria, rheumatoid arthritis and systemic lupus erythematosus. Hydroxychloroquine lung disease Otis pregnancy hydroxychloroquine Plaquenil and your eyes Research has shown that your risk of developing retinopathy is higher the longer you are taking Plaquenil. In fact, the incidence of retinal toxicity rises sharply in people that have taken it between 5 and 7 years. As a result, baseline testing should occur within the first year of taking the drug and then annually at the five-year mark. Risk factors that increase the chance of hydroxychloroquine retinopathy include daily dosage, cumulative dose, renal or liver disease, age, and previous retinal disease 9. A daily dose of 6.5mg/kg ideal body weight places patients at higher risk, but a daily dose below this level did not preclude the patient from developing toxicity after many years of treatment. Over 80 % of patients taking 4-aminoquinolines 4AQs have risk factors for retinopathy. The most important risk factor is the adjusted daily dose. Taking hydroxychloroquine at a dose less than 6.5 mg/kg/d based on the lesser of actual and ideal body weight is typically safe. It is imperative that patients and physicians are aware of and watch for this drug’s ocular side effects. Retinal toxicity from hydroxychloroquine is rare, but even if the medication is discontinued, vision loss may be irreversible and may continue to progress. Plaquenil retinopathy risk factors The Risk of Retinal Toxicity with Plaquenil - Sjogren's, Hydroxychloroquine Plaquenil Toxicity and. Chloroquine and release of cargoWhat type muscle weakness with plaquenil Melles R, Marmor M. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132121453-60. 6. Michaelides M, Niam H, Stover P, et al. Retinal toxicity associated with hydroxychloroquine and chloroquine risk factors, screening, and progression despite cessation of therapy. How to Succeed in Plaquenil Screenings. Risk Factors for Hydroxychloroquine and Chloroquine.. Hydroxychloroquine and Chloroquine Retinopathy.. Jan 01, 2020 For individuals with significant risk factors daily dose of hydroxychloroquine sulfate greater than 5.0 mg/kg base of actual body weight, subnormal glomerular filtration, use of tamoxifen citrate or concurrent macular disease monitoring should include annual examinations which include BCVA, VF and SD-OCT. Our results show that the prevalence of hydroxychloroquine retinopathy is much higher than previously recognized and depends on risk factors such as daily dose, duration of use, and kidney disease. The results also suggest the need to revise the way that dosage is calculated to minimize risk. A cookie-cutter approach to dosing Plaquenil hydroxychloroquine, Sanofi-Aventis, an anti-malarial drug that has been used as a treatment for systemic lupus erythematosus and rheumatoid arthritis.